GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Cyclically Adjusted Book per Share

BCTX (BriaCell Therapeutics) Cyclically Adjusted Book per Share : $15.30 (As of Jan. 2025)


View and export this data going back to 2023. Start your Free Trial

What is BriaCell Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BriaCell Therapeutics's adjusted book value per share for the three months ended in Jan. 2025 was $1.223. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $15.30 for the trailing ten years ended in Jan. 2025.

During the past 12 months, BriaCell Therapeutics's average Cyclically Adjusted Book Growth Rate was -78.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -66.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -47.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BriaCell Therapeutics was -8.20% per year. The lowest was -66.50% per year. And the median was -16.25% per year.

As of today (2025-05-17), BriaCell Therapeutics's current stock price is $2.94. BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2025 was $15.30. BriaCell Therapeutics's Cyclically Adjusted PB Ratio of today is 0.19.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BriaCell Therapeutics was 0.19. The lowest was 0.00. And the median was 0.00.


BriaCell Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for BriaCell Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Cyclically Adjusted Book per Share Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 750.26 650.35 425.68 191.61 22.63

BriaCell Therapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.43 22.54 22.63 17.86 15.30

Competitive Comparison of BriaCell Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, BriaCell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

BriaCell Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BriaCell Therapeutics's adjusted Book Value per Share data for the three months ended in Jan. 2025 was:

Adj_Book= Book Value per Share /CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=1.223/127.4427*127.4427
=1.223

Current CPI (Jan. 2025) = 127.4427.

BriaCell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201504 81.368 99.710 103.999
201507 61.000 100.579 77.292
201510 45.947 100.500 58.265
201601 27.474 100.184 34.949
201604 56.800 101.370 71.410
201607 39.350 101.844 49.241
201610 80.700 102.002 100.828
201701 61.909 102.318 77.111
201704 65.708 103.029 81.278
201707 31.250 103.029 38.655
201710 39.480 103.424 48.649
201801 18.800 104.056 23.025
201804 67.114 105.320 81.211
201807 27.000 106.110 32.428
201810 10.056 105.952 12.096
201901 -16.806 105.557 -20.290
201904 14.614 107.453 17.333
201907 -15.659 108.243 -18.436
201910 -17.000 107.927 -20.074
202001 -47.125 108.085 -55.565
202004 -57.417 107.216 -68.249
202007 -74.938 108.401 -88.101
202010 -66.059 108.638 -77.493
202101 -71.196 109.192 -83.096
202104 27.528 110.851 31.648
202107 27.183 112.431 30.812
202110 54.042 113.695 60.577
202201 44.873 114.801 49.814
202204 44.267 118.357 47.665
202207 9.980 120.964 10.515
202210 9.985 121.517 10.472
202301 -1.238 121.596 -1.298
202304 -5.693 123.571 -5.871
202307 -3.546 124.914 -3.618
202310 2.555 125.310 2.598
202401 -7.580 125.072 -7.724
202404 -5.601 126.890 -5.625
202407 -1.954 128.075 -1.944
202410 1.676 127.838 1.671
202501 1.223 127.443 1.223

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


BriaCell Therapeutics  (NAS:BCTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BriaCell Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.94/15.30
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BriaCell Therapeutics was 0.19. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BriaCell Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Traded in Other Exchanges
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Executives
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0